Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05816-7 ↗Kurz gefasst
Leserbrief in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yan Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 11 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
- Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
- Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. xya3shg@163.com.
Zitieren
APA
Li, Y., Zhang, Q., & Shao, H. (2024). Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene. Annals of Hematology. https://doi.org/10.1007/s00277-024-05816-7
Vancouver
Li Y, Zhang Q, Shao H. Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene. Annals of Hematology. 2024. doi:10.1007/s00277-024-05816-7
BibTeX
@article{Li2024,
author = {Li, Yan and Zhang, Qin and Shao, Haigang},
title = {Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05816-7}
}
EUVIMED